<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432484</url>
  </required_header>
  <id_info>
    <org_study_id>RA-2005-001</org_study_id>
    <nct_id>NCT00432484</nct_id>
  </id_info>
  <brief_title>Lingzhi and Sen Miao San for the Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>Lingzhi (Ganoderma Lucidum) and Sen Miao San Supplementation in Rheumatoid Arthritis(RA): An Animal Model and A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy of TCM as an effective supplement in addition to the traditional
      treatment in RA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective, double-blind, randomized, placebo-controlled study in patients with RA.
      It consists of a 24 - weeks period of randomized double-blind treatment of either TCM(Lingzhi
      and Sen Miao San)or placebo.

      Primary outcome is assessed by showing a clinical response of at least 20% and 50% as defined
      by the American College of Rheumatology (ACR) criteria.Secondary outcome is defined as the
      changes in the number of swollen and tender joint counts, and the levels of ESR, CRP, the
      inflammatory markers, cytokine levels and oxidative stress.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>We assessed the proportion of patients showing a clinical response of at least 20% and 50% as defined by the American College of Rheumatology (ACR) criteria (20).</measure>
    <time_frame>wk52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the number of swollen and tender joint counts, and the levels of ESR, CRP, the inflammatory markers, cytokine levels and oxidative stress will be assessed as secondary outcomes.</measure>
    <time_frame>wk52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with Lingzhi(Granoderma Lucidum) and Sen Miao San</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lingzhi and Sen Miao San</intervention_name>
    <description>G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pingyin English name</other_name>
    <other_name>Lingzhi Ganoderma lucidum seu Japonicum</other_name>
    <other_name>Cangzhu Atractylodes lancea</other_name>
    <other_name>Huangbo Phellodendron amurense</other_name>
    <other_name>Niuxi Achyranthes bidentata B1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfilled the 1987 American College of Rheumatology (ACR) criteria for RA.

          -  The presence of 2 or more swollen or tender joints, based on 28-joint count.

          -  Morning stiffness lasting for 30 minutes.

          -  Erythrocyte sedimentation rate (ESR) of 28 mm/hour, despite treatment with disease
             modifying agent including MTX, sulphasalazine, hydroxychloroquine, auranofin or
             azathioprine were recruited into the study.

          -  Patients taking glucocorticoids (prednisone &lt; 7.5 mg/day) and/or nonsteroidal
             antiinflammatory drugs must have been taking a stable dosage for at least 4 weeks
             before entering the trial and were required to take the same dosage throughout the
             trial.

          -  Patients had radiographic erosive diseases.

        Exclusion Criteria:

          -  Patients who are pregnant or nursing mothers.

          -  Severe liver disease (e.g cirrhosis, chronic active hepatitis)

          -  Renal impairment (serum creatinine level &gt; 150mmol/L)

          -  Known hypersensitivity to herbal medicine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund K Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Institute of Chinese Medicine</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2007</study_first_submitted>
  <study_first_submitted_qc>February 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2007</study_first_posted>
  <last_update_submitted>May 6, 2008</last_update_submitted>
  <last_update_submitted_qc>May 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lai-Shan Tam</name_title>
    <organization>The Chinese University of Hong Kong</organization>
  </responsible_party>
  <keyword>Lingzhi</keyword>
  <keyword>Sen Miao San</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

